The PRECICE Stryde recall, explained — and what it means in 2026

Stryde launched commercially in 2018 as the heavier-duty sibling of the PRECICE 2 platform. The pitch to patients was a meaningful one: full weight-bearing during the distraction phase. Patients on PRECICE 2 are restricted to partial weight-bearing for 6-10 weeks while the bone lengthens. Stryde was engineered with a stainless-steel core that promised the same magnetically-driven internal mechanism with the strength to bear full body weight from day one. That meant crutches earlier, then a stick, then walking unaided weeks before the PRECICE 2 timeline.

It was a real advance on paper. Surgeons at high-volume US and European centers adopted it quickly. Series reported faster functional recovery, comparable lengthening rates, and the same telescoping mechanism patients already understood. Between 2018 and early 2021, Stryde was implanted in an estimated several thousand patients worldwide. NuVasive, the manufacturer at the time, marketed it as the next generation of the PRECICE platform, and most surgeons treated it as such.

The trouble was not in the lengthening mechanism. It was in the metal.

Stryde used a stainless-steel core with a biocompatible coating at the telescoping junction, the sliding joint where one half of the nail extends out of the other. The coating was intended to prevent direct contact between the steel and the surrounding bone and to suppress the immune response that any orthopedic implant provokes. In a subset of patients, that coating failed.

The failure mode was documented in a 2021 Bone & Joint Research paper (PMC8333033) led by surgeons at Hospital for Special Surgery in New York and the International Center for Limb Lengthening in Baltimore. The team studied 57 lengthened segments and 24 retrieved Stryde nails. Radiographic osteolysis adjacent to the telescoping junction appeared in 20 of 57 segments (35%) at a mean of 9.5 months post-op. Of the 24 nails actually removed and analysed under scanning electron microscopy, 20 (83%) showed macroscopic corrosion at the junction. Pitting corrosion and crevice corrosion were the dominant patterns. Energy-dispersive X-ray spectroscopy identified chromium as the main metallic element in the corrosion products. Histological examination of the surrounding tissue showed macrophages and multinuclear giant cells containing brown metallic particles, the classic immune response to metal debris.

The clinical picture varied. Some patients had radiographic osteolysis without any pain. Some had pain without dramatic radiographic changes. Some required earlier-than-planned implant removal because the discomfort did not resolve. The fundamental concern was that bone was being lost adjacent to the implant in a substantial minority of patients, and that the long-term consequence of that bone loss was unknown.

The regulatory sequence is worth understanding because it explains why some clinics still had Stryde nails in stock months after the headline date.

Existing Stryde patients should follow their surgeon's monitoring protocol. The standard of care across high-volume US and European centers in 2026 looks like this. Radiographic imaging every 6-12 months for at least 3 years post-op, focused on the telescoping junction. Symptom review at each follow-up, pain near the implant, restricted range of motion at the adjacent joint, or any change in gait. Blood work for inflammatory markers if symptoms develop. Elective implant removal once consolidation is complete (typically 12-18 months post-implant), even if asymptomatic, most centers now recommend removal rather than long-term retention. A 2023 Strategies in Trauma and Limb Reconstruction paper (PMC10628610) reported that bone healing was not impaired despite the radiographic and clinical symptoms, which means most patients can proceed with a normal removal schedule. The 2022 explantation study (PMC9221827) reported that focal osteolysis substantially resolved within months of removal in most patients, the bone returns once the corrosion stops.

Reported symptomatic rates vary. Roughly 5-10% of Stryde patients across published series experienced pain or radiographic changes warranting earlier-than-planned removal. The remaining 90-95% had no clinical issue beyond the routine PRECICE-platform expectations. None of this is reassurance to skip imaging, the radiographic signature can be silent, but it is calibration on the actual risk to patients who already have the device.

If you had Stryde implanted and are not currently under the care of a surgeon, the most important action is to schedule an imaging review. The Paley Institute, HSS, the Rubin Institute (Baltimore), and Acibadem Healthcare Group in Istanbul have all confirmed in writing that they will evaluate existing Stryde patients regardless of where the original implant was placed. Contact information for those centers is in our clinic directory.

Two devices now occupy the space Stryde was designed to fill. PRECICE 2 is the established workhorse, same magnetic distraction mechanism, no weight-bearing during the distraction phase, and the longest track record of any internal nail. It is the cosmetic-LL default at most US, German, UK, and Israeli centers in 2026. PRECICE Max is the newer generation, first implanted in the US in late 2023. It uses a stronger titanium platform with greater length capacity and durability than PRECICE 2 but does not restore the weight-bearing-during-distraction capability that was Stryde's selling point. Both PRECICE 2 and PRECICE Max are manufactured by Globus Medical's NuVasive Specialized Orthopedics division and are FDA-cleared with active distribution.

Neither replaces Stryde in the precise sense, full weight-bearing during distraction is not currently available in any cleared device. Patients who specifically need that capability (rare in cosmetic indication) are advised on hybrid LON, which combines an external fixator with an internal nail and allows earlier partial weight-bearing through the fixator. The Turkish centers that lead LON practice have not adopted any Stryde-equivalent because LON itself provides comparable functional recovery without the corrosion risk.

We have caught a handful of clinics in our 44-clinic verification process whose method pages or marketing copy still listed Stryde in 2026. In every case the clinic confirmed on direct enquiry that they no longer implant the device, the website was simply out of date. That is the explanation in most cases. A small minority of clinics outside the US continued implanting Stryde inventory into 2022. We are not aware of any active Stryde implantation at our verified clinics in 2026, but the directory is updated quarterly and editorial notes are published for any clinic that historically used Stryde without addressing it on its method page.

If you are evaluating a clinic that still has Stryde in its written materials, treat the listing as a data point and ask directly. The five-question checklist below is the screening protocol.

These questions filter the clinics that managed the Stryde recall properly from the clinics that hope the question does not come up. None require medical training to evaluate the answer.

First: do you still implant Stryde? The answer in 2026 should be a clear no. Any answer that includes a qualifier ("only in specific cases", "for selected patients", "in jurisdictions where it is available") is a red flag.

Second: for existing Stryde patients in your practice, what is your monitoring schedule? The expected answer is imaging every 6-12 months for at least 3 years post-op, with elective removal once consolidation is complete. A clinic that cannot articulate a written protocol has not built one.

Third: what is your threshold for prophylactic Stryde removal? In 2026, the standard answer is elective removal at 12-18 months post-op for all asymptomatic patients with imaging-confirmed osteolysis. A clinic that says "only if symptoms develop" is operating below current best practice.

Fourth: have you evaluated other surgeons' Stryde patients? Centers that have an active referral protocol for outside Stryde patients, Paley Institute, HSS, Rubin Institute, Acibadem, have built operational experience that smaller clinics have not. This question separates centers with depth from centers with a website note.

Fifth: what is your follow-up protocol for the next 5 years? The 2026 standard is annual imaging review through year 5 post-implant for any patient who had Stryde, even if the implant was removed. Long-term bone density and joint outcomes are still being characterised in the literature, and any clinic that has thought about Stryde will have a 5-year follow-up framework written down.

Five years after the recall, the Stryde story is a useful case study for any patient evaluating cosmetic limb lengthening in 2026. Three lessons apply.

First, manufacturer reputation does not equal patient safety. NuVasive was, and Globus Medical still is, among the most respected names in spine and orthopedic implants. Stryde launched with full FDA clearance, supportive early case series, and adoption by the leading surgeons in the field. The corrosion problem was not visible until enough patients had been followed long enough to see the radiographic signature. New implants in any orthopedic category carry an irreducible risk that the first 5,000 patients are the surveillance cohort. Patients who insist on the newest device by default may not understand they are signing up for that role.

Second, the publication-to-recall lag was fast and that is the system working. The first peer-reviewed series flagging osteolysis appeared in late 2020. The voluntary action came in February 2021. The FDA Class I classification came in April. That is roughly six months between identifiable signal and the strongest regulatory action available. Patients who saw the timeline as a regulatory failure are reading it backwards, the device was withdrawn before the cohort of affected patients grew significantly.

Third, surgeon transparency matters more than device branding. The surgeons who flagged the problem to the manufacturer, at HSS, Rubin Institute, Paley, are the same surgeons our directory lists today as Tier 1 centers. The clinics that took longer to acknowledge the recall, or that continued implanting through 2022 in markets where it was technically still available, are the ones the directory either does not list or lists with an editorial note. The recall, in other words, helped sort the directory. Five years later that sorting still applies.